Icon

IBTROZI - (200MG)

TALETRECTINIB ADIPATE None
200MG
Less Than $1000 mn
None None
None None
None None
IBTROZI is a kinase inhibitor indicated for the treatment of adult patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC).
Yes
IBTROZI Patent 1 Patent 2
*** *********

Download ParaIV Report


Download ParaIV Detailed Report


To get detailed report Contact Us

ParaIV Advanced Search






Drug Name Generic Name Dosage Route of Administration Probable FTF Known Para IV Filers Other ANDA Developers

Please contact contact@researchdelta.com to get more details.